Table 1.
Variables | Mean (Median), Percentage % (number) | Range, (IQR) |
---|---|---|
Age | 44 (48) | 13–77 (29–57) |
Gender | ||
Male | 42.4% (14) | |
Female | 57.6% (19) | |
Indications of ECMO | ||
Respiratory causes | 42.4% (14) | |
Viral pneumonia | 18.2% (6) | |
Bacterial pneumonia | 6.1% (2) | |
Massive hemoptysis | 6.1% (2) | |
Other respiratory diagnosis | 3.0% (1) | |
Extrapulmonary ARDS | 3.0% (1) | |
Chest injuries | 3.0% (1) | |
Asthma | 3.0% (1) | |
Cardiovascular causes | 57.6% (19) | |
Acute myocardial infarction | 6.1% (2) | |
Myocarditis | 9.1% (3) | |
Severe valvular regurgitation/stenosis | 9.1% (3) | |
Postcardiotomy cardiogenic shock | 27.3% (9) | |
Amniotic fluid embolism | 3.0% (1) | |
Massive pulmonary embolism | 3.0% (1) | |
Severe pulmonary hypertension | 3.0% (1) | |
CRRT while on ECMO | 50% (14)a | |
Mode | ||
VV | 33.3% (11) | |
VA | 63.6% (21) | |
VV converted to VA | 3.0% (1) | |
Clinical signs of hemolysis while on ECMO | 6.1% (2) | |
Bleeding complications (overall) | 24.2% (8) | |
Cannulation site | 3.0% (1) | |
Tracheostomy site | 3.0% (1) | |
Sternotomy site requiring resternotomy | 6.1% (2) | |
Gastrointestinal | 3.0% (1) | |
Hemothorax | 9.1% (3) | |
Number of days on ECMO | 8.8 (4.5) | 1–37 (2–11) |
Wean from ECMO | 53.1% (17)b | |
ICU length of stay (days) | 14.0 (11.5) | 1–50 (3–16) |
Death within ICU | 48.5% (16) | |
Hospital deathc | 48.5% (16) | |
Hemolysisd | 6.1% (2) | |
CO‐Hb <3% | 0% (0) | |
CO‐Hb >3% | 100% (2) | |
Without Hemolysise | 93.9% (31) | |
CO‐Hb <3% | 96.8% (30) | |
CO‐Hb >3% | 3.2% (1) |
IQR, interquartile range; ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress syndrome
CRRT after ECMO; CRRT is provided after ECMO is initiated, five patients’ data are missing.
Wean from ECMO; liberation from ECMO without death in the next 7 days and second run ECMO, one patient's data are missing.
Hospital death; death before hospital discharge to home or a convalescent hospital.
Hemolysis; plasma‐free Hb >50 mg/dL.
Without Hemolysis; plasma‐free Hb <50 mg/dL.